|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2006-6-7
|
|
pubmed:abstractText |
Emerging data suggest that treatment outcomes with aromatase inhibitors (AIs) and/or tamoxifen may differ for tumors that express both the estrogen receptor (ER) and the progesterone receptor (PR) (ER+/PR+) compared with those that lack PR expression (ER+/PR-). However, the optimal sequencing of AIs and tamoxifen as adjuvant therapy is not known and may differ for biologic subsets of cancers.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2006 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
106
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2576-82
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16703595-Age Factors,
pubmed-meshheading:16703595-Aged,
pubmed-meshheading:16703595-Aged, 80 and over,
pubmed-meshheading:16703595-Antineoplastic Agents, Hormonal,
pubmed-meshheading:16703595-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16703595-Aromatase Inhibitors,
pubmed-meshheading:16703595-Breast Neoplasms,
pubmed-meshheading:16703595-Chemotherapy, Adjuvant,
pubmed-meshheading:16703595-Cross-Over Studies,
pubmed-meshheading:16703595-Decision Support Techniques,
pubmed-meshheading:16703595-Disease-Free Survival,
pubmed-meshheading:16703595-Drug Administration Schedule,
pubmed-meshheading:16703595-Female,
pubmed-meshheading:16703595-Humans,
pubmed-meshheading:16703595-Markov Chains,
pubmed-meshheading:16703595-Middle Aged,
pubmed-meshheading:16703595-Models, Statistical,
pubmed-meshheading:16703595-Models, Theoretical,
pubmed-meshheading:16703595-Neoplasm Staging,
pubmed-meshheading:16703595-Odds Ratio,
pubmed-meshheading:16703595-Postmenopause,
pubmed-meshheading:16703595-Randomized Controlled Trials as Topic,
pubmed-meshheading:16703595-Receptors, Progesterone,
pubmed-meshheading:16703595-Tamoxifen,
pubmed-meshheading:16703595-Time Factors,
pubmed-meshheading:16703595-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
|
|
pubmed:affiliation |
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts 02115, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
